610-701-9243 wche@wche1520.com

U.S. Attorney William M. McSwain announced Monday that Pentec Health, Inc. has agreed to pay the United States $17 million to settle allegations that the company submitted false claims to Medicare and other government healthcare programs. Headquartered in Glen Mills, Pennsylvania, Pentec furnishes a range of renal and specialized pharmacy compounding services to individuals with end stage renal disease. The United States alleges that from 2007 to 2018, Pentec billed Medicare and other federal healthcare programs for excessive amounts of product wasted during the compounding of a drug called Proplete, and Pentec routinely waived patient copayments and deductible obligations in order to induce the prescription and use of Proplete. Pentec also submitted duplicate and improperly coded claims to the Federal Employee Health Benefits Program. Maureen Dixon, Special Agent in Charge of Health and Human Services, Office of Inspector General in Philadelphia said that: “Compounding pharmacies play an integral role in the delivery of quality health care services and are required to follow rules designed to protect patients and prevent the waste of taxpayer funds.”